Pharmaceutical Supplier for Central Asia: A Guide to European Medicine Supply for Kazakhstan and Uzbekistan

A pharmaceutical supplier serving Central Asia faces a market that has undergone remarkable transformation over the past decade. The pharmaceutical market of Uzbekistan reached an annual volume of USD 2.14 billion in the twelve months to September 2025, compared to USD 888 million in 2018 — an average annual growth rate of over 13.4 percent. Uzbekistan has emerged as the most dynamic pharmaceutical market in the region and, alongside Kazakhstan, is the primary driver of regional demand growth.

Despite localization efforts, the Central Asian market remains structurally import-dependent. In Uzbekistan, approximately 89 percent of pharmaceutical sales by value are generated by imported products. This structural import dependency creates significant and sustained opportunity for European pharmaceutical suppliers.

Recent regulatory reforms have reinforced this opportunity. Since October 2025, Uzbekistan has introduced a fast-track registration mechanism for medicines previously approved by regulatory authorities with high WHO status, including the European Union. This reform significantly accelerates entry for innovative European medicines and reduces duplicative registration procedures.

In this article, we explain what characterises the Central Asian pharmaceutical market, what regulatory requirements apply in the key countries, what challenges arise in supplying medicines from Europe to this region, and what criteria matter most when selecting a European supply partner.

Lenus Health is a pharmaceutical wholesaler based in Germany with years of active presence in Central Asian markets. We are not simply a distant European supplier. We have established local partners in Uzbekistan, Kyrgyzstan, and Tajikistan, work directly with ministries of health in the region, and have first-hand knowledge of the product registration process in each market. This on-the-ground experience is what sets us apart from other European suppliers.

For international supply and commercial inquiries regarding this product, please contact the Lenus Health sales team.

Table of Contents

1. Why the Central Asian Pharmaceutical Market Attracts European Suppliers
2. Key Markets: Kazakhstan, Uzbekistan and Beyond
3. Regulatory Requirements: Country Comparison Table
4. Main Challenges in Supplying Medicines from Europe to Central Asia
5. High-Demand Medicine Categories in Central Asia
6. Registration and Import Pathways
7. The Role of the European Supplier in the Regional Supply Chain
8. How to Select the Right European Supply Partner
9. Conclusion
10. Frequently Asked Questions

1. Why the Central Asian Pharmaceutical Market Attracts European Suppliers

The Central Asian pharmaceutical market is projected to grow at 3.29 percent annually, reaching USD 1.822 billion by 2029. This growth, combined with the region’s structural import dependency, creates three key factors of attractiveness for European suppliers.

Three primary factors make this market compelling:

• Structural import dependency: In Uzbekistan, 89 percent and in Kazakhstan a comparable share of pharmaceutical sales by value are generated by imported products. Local manufacturing capacity cannot fill this gap in the near term.
• Regulatory reforms aligned with European standards: Uzbekistan’s fast-track mechanism from October 2025 for medicines approved by WHO-trusted regulators including the EU reduces duplicative registration procedures. The new requirement that GMP compliance must be demonstrated for new drug registration also works in favour of European-certified suppliers.
• Consumption mix shifting towards higher-quality medicines: The share of low-cost medicines in Uzbekistan is declining while the segment of medicines priced above USD 10 is strengthening, reflecting growing demand for branded original medicines and complex therapies.

For European suppliers, this combination of high import dependency, regulatory reforms aligned with European standards, and a consumption mix shifting towards quality medicines makes Central Asia a market with genuine, growing opportunity.

2. Key Markets: Kazakhstan, Uzbekistan and Beyond

The Central Asian pharmaceutical market is composed of several economies of different sizes. Understanding the specific characteristics of each market is strategically important for European suppliers planning their regional approach.

Key characteristics of the main markets:

• Uzbekistan: The largest and fastest-growing market in the region. Its retail pharmaceutical market is 54 percent larger than Kazakhstan’s by value, with growth exceeding 31 percent. It is positioning itself as the regional pharmaceutical hub for neighbouring smaller countries.
• Kazakhstan: Germany is one of the three largest non-CIS pharmaceutical suppliers to Kazakhstan, indicating that European-origin medicines already hold an established position in this market. Kazakhstan is a member of the Eurasian Economic Union, which creates specific regulatory requirements.
• Kyrgyzstan, Tajikistan and Turkmenistan: Smaller markets that lag significantly behind in scale. They are often supplied through Uzbek or Kazakh distributors. Turkmenistan, with the least transparent regulatory system, is the most complex market in the region.

Recognising these differences before beginning the registration and export process can prevent significant time and cost loss.

3. Regulatory Requirements: Country Comparison Table

One of the most important things European suppliers must understand is that each Central Asian country has its own independent regulatory pathway. The following table provides a comparison of the key requirements:

What this table makes clear is that Uzbekistan is becoming the more accessible entry point for European medicines, while some countries like Turkmenistan remain significantly more complex. An effective market entry strategy typically starts with Kazakhstan or Uzbekistan and uses that as a foundation for expansion to smaller markets.

4. Main Challenges in Supplying Medicines from Europe to Central Asia

Supplying medicines from Europe to Central Asian markets involves specific challenges that every supplier must understand in advance. Recognising these challenges helps prevent unexpected delays.

The main challenges you will encounter in this supply chain:

• Eurasian Economic Union requirements: Kazakhstan and Kyrgyzstan are EAEU members. Medicines must comply with EAEU requirements in addition to national requirements. In practice, this may require additional documentation such as EAC certification.
• Translation and notarisation of documents: All documentation must be translated into Russian and typically into the national language of the destination country, and notarised. This requirement is frequently unexpected for European suppliers without prior experience in these markets.
• Multi-stage distribution chains: In many Central Asian countries, the distribution chain runs from the official importer to a distributor and then to a pharmacy or hospital. Each stage has its own licences and requirements.
• Government tender delays: A significant share of hospital medicines is purchased through government tenders. Payment delays and frequent changes to tender requirements are operational realities.
• Inconsistent cold chain infrastructure: Cold chain transport infrastructure in some parts of the region has not yet reached European standards. This risk must be factored into logistics planning for temperature-sensitive medicines.

Despite these challenges, a European supplier with complete documentation and sufficient regional experience can manage most of them through careful planning and transparent communication.

5. High-Demand Medicine Categories in Central Asia

For European suppliers, understanding the highest-demand categories in the Central Asian market helps prioritise product registration and maximise the return on investment in market entry.

The categories with the highest demand in Central Asian markets:

• Cardiovascular and metabolic: Cardiovascular disease and diabetes have high prevalence across the region. Antihypertensives, statins, and diabetes medicines have sustained structural demand.
• Antibiotics: With high rates of respiratory infections in the region, quality European antibiotics have consistent demand.
• Oncology: New treatments for oncology and rare diseases are increasingly being included in national formularies across the region.
• Quality European generics: High-quality generics maintain strong demand as governments and health insurers prioritise cost-effective care.
• Psychiatric medicines: With improving healthcare infrastructure, demand for psychiatric medicines is growing steadily.

Understanding these categories helps European suppliers align their export portfolio with actual market needs and plan registration priorities accordingly.

6. Registration and Import Pathways

For importers and distributors in Central Asia sourcing medicines from Europe, understanding the different import pathways is operationally important. Choosing the wrong pathway can lead to significant delays.

The main import pathways are:

• Full product registration: The most reliable pathway for medicines intended for regular import. In Uzbekistan, the October 2025 fast-track mechanism allows medicines previously approved by EU and other WHO-trusted regulators to be registered without duplicative procedures.
• EAEU centralised registration: For EAEU member countries including Kazakhstan, registration through the centralised EAEU process is valid across all member states. This can be more efficient than separate national registration for suppliers targeting multiple EAEU members.
• Government tenders: Government hospital purchases are conducted via tender. Product registration before the tender is mandatory.
• Emergency import: For medicines not yet registered but needed urgently, emergency import pathways exist in most countries in the region.

For every one of these pathways, complete European documentation including CPP, CoA, GMP certificate, and batch release records is mandatory. All documentation must be translated into Russian and notarised.

7. The Role of the European Supplier in the Regional Supply Chain

Unlike the GCC where each country typically requires a separate local agent, Central Asia allows for a more centralised approach. Uzbekistan and Kazakhstan can function as regional distribution hubs for smaller neighbouring markets.

Key roles that a European supplier plays in this supply chain:

• Providing complete EMA documentation that forms the basis of the registration process in each destination country
• Supporting the translation and notarisation process for regional language requirements
• Guaranteeing supply continuity for medicines in hospital formularies and national insurance programmes
• Managing cold chain logistics across the longer transport distances involved in Central Asian supply
• Supporting the registration process by responding to questions from regulatory authorities

Lenus Health is familiar with the regulatory requirements of Kazakhstan and Uzbekistan and can prepare export documentation in a format that facilitates the registration process in these markets.

8. How to Select the Right European Supply Partner

For importers and distributors in Central Asia, selecting the right European partner has strategic importance. An unsuitable partner can result in long registration delays and documentation problems.

The main criteria for evaluating a European pharmaceutical supplier for Central Asian markets:

• Familiarity with EAEU and local requirements: A supplier who understands Kazakhstan, Uzbekistan, and EAEU registration processes significantly reduces the risk of delays.
• Complete, translation-ready documentation: Documentation that is readily translatable into Russian and suitable for notarisation.
• WDL and GMP: A valid Wholesale Dealer License and manufacturer GMP certificates are the foundation of trust for Central Asian regulatory authorities.
• Capacity to supply appropriate volumes: Many government tenders in the region require high volumes.
• Experience in CIS or Central Asian markets: Prior experience in CIS or Central Asian markets is a meaningful advantage.

If your organisation requires pharmaceutical supply from Europe for Central Asian markets, we welcome the opportunity to discuss your specific requirements.

Conclusion
The Central Asian pharmaceutical market is at a pivotal point of transformation. Uzbekistan, with its explosive growth and regulatory reforms that accelerate European medicine entry, has become a priority market. Kazakhstan, with Germany already established as one of its main suppliers, offers another market with genuine opportunity for European pharmaceutical suppliers.

The region’s high import dependency, regulatory reforms aligned with international standards, and a consumption mix shifting towards higher-quality medicines all work in favour of European suppliers. Success in this market requires a precise understanding of each country’s regulatory requirements, complete documentation, and selecting the right local distribution partner.

If you are a pharmaceutical manufacturer:

If your pharmaceutical company has products you want to introduce to the markets of Uzbekistan, Kyrgyzstan, or Tajikistan, Lenus Health can clear the path for you. We handle product registration in these countries, manage the local distribution network, and thanks to our direct relationships with regional ministries of health, we move the process faster and with greater certainty. Get in touch with our team to start the conversation.

If you are an importer or distributor:

We know what Central Asian markets need and which products perform well there. Based on a precise understanding of local demand, the Lenus Health team identifies the best European products suited to your specific market. Not a generic catalogue, but a tailored solution built around the real needs of your market.

For international supply and commercial inquiries regarding this product, please contact the Lenus Health sales team.

Frequently Asked Questions

• Is EMA documentation sufficient for product registration in Kazakhstan and Uzbekistan?
  EMA documentation forms a very strong basis for the registration process but is not sufficient on its own. Kazakhstan is an EAEU member and has additional EAEU requirements. In Uzbekistan, since October 2025, medicines previously approved by WHO-trusted regulators including the EU can use a fast-track registration pathway. In all cases, documentation must be translated into Russian and notarised.
• What impact does the Eurasian Economic Union have on medicine imports?
  The EAEU has created a shared regulatory framework for member countries including Kazakhstan and Kyrgyzstan. Medicines registered through the centralised EAEU process are valid across all member states. For European suppliers targeting multiple EAEU members, this pathway can be more efficient than separate national registration in each country.
• How long does product registration in Uzbekistan take?
  Under the previous system, the registration process took 12 to 18 months. With the new fast-track mechanism introduced in October 2025 for medicines approved by WHO-trusted regulators including the EU, this timeline has been reduced significantly. Documentation must be complete and in the correct format to qualify for the accelerated pathway.
• Does each Central Asian country require a separate local agent?
  In most Central Asian countries, having an authorised local agent or importer is mandatory. However, unlike the GCC, in Central Asia it is possible to use an Uzbek or Kazakh importer as a regional distribution hub for smaller neighbouring markets. Selecting a local importer with sufficient regulatory knowledge and distribution network is one of the most important strategic decisions.
• What documents need to be translated into Russian?
  Typically all core documents including CPP, CoA, GMP certificate, batch release records, and product documentation need to be translated into Russian and notarised. Some countries such as Kazakhstan and Uzbekistan may also require translation into the national language.
• How can we participate in government tenders in Central Asia?
  Participation in government tenders requires prior product registration. The participating entity typically needs to be either a local company or partner with a local company. A European supplier can support this process by introducing a qualified local partner and providing complete documentation.